58.com Inc (ADR) (NYSE:WUBA) shares were up 4.8% at $43.50 after the technology company reported better-than-expected Q3 results and Q4 guidance. Basic and diluted earnings per ADS attributable to ordinary shareholders were $0.07. Non-GAAP net income was $7.8 million, or $0.09 per share, compared with non-GAAP net income of $9.3 million, or $0.13, in the same quarter of 2013. Analyst estimates called for a loss of $0.04 per share, according to Capital IQ.Total revenues were $72.0 million, a 72.9% increase from the same period last year; exceeding guidance of $66.0 million to $68.0 million and better than Street estimates of $68 million. Based on the company's current operations, total revenues for the fourth quarter of 2014 are expected to be between $74.5 million and $77.0 million, representing a year-over-year increase of 65% to 70%. The Street sees revenue at $71.5 million for Q4. 58.com Inc (ADR) (NYSE:WUBA) trades in a 52-week range of $27.66 to $58.89.Click here for a free comprehensive Trend Analysis ReportOcular Therapeutix Inc (NASDAQ:OCUL), a biopharmaceutical company focused on the development and commercialization of therapies for diseases and conditions of the eye, has announced enrollment of the first patients in a Phase 2b clinical trial evaluating Sustained Release Travoprost (OTX-TP) for the reduction of elevated intraocular pressure in patients with open-angle glaucoma and ocular hypertension.The prospective, multicenter, randomized study is designed to evaluate 80 patients at 10 clinical sites for the safety and efficacy of the OTX-TP as compared to timolol. Ocular Therapeutix Inc (NASDAQ:OCUL) said that study efficacy endpoints include difference in the mean intraocular pressure change between the treatment groups from baseline at multiple timepoints throughout the study. Previous pilot and Phase 2a clinical trials evaluating OTX-TP showed robust reductions in intraocular pressure for up to three months, similar to results found with twice-daily timolol dosing. Over the past 52 weeks, the company has traded between $11.90 and $16.97.Click here for a free comprehensive Trend Analysis ReportEncana Corporation (USA) (NYSE:ECA), Canada's biggest natural-gas producer, reported Q3 operating earnings below Street forecasts and revenues above the consensus. Q3 operating earnings jumped 87% to $281 million, or $0.38 per share from $150 million, or $0.20 per share, yet fell short of the consensus of $0.44 per share. The 87% increase in operating profit is attributed to higher production of natural gas and oil.Q3 net income attributable to shareholders soared to $2.8 billion, or $3.79 per share from $188 million, or $0.25 per share in the year-ago period, primarily due to a $2.4 billion gain related to asset divestitures. Encana Corporation (USA) (NYSE:ECA) quarterly revenues, excluding royalties, climbed to $2.29 billion from $1.39 billion, topping the consensus of $1.7 billion. In Q3, cash flow climbed 22% to $807 million, or $1.09 per share. The company's board also declared an unchanged quarterly dividend of $0.07 per share, payable on Dec. 31 to holders of record on Dec. 15.Click here for a free comprehensive Trend Analysis Report
Discover Hidden Gems
Don't miss the next big opportunity. Subscribe for timely alerts on potential market movers.
